CORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient buyer: the dominant driver remains the FDA Complete Response Letter/\u201crejection\u201d overhang and related legal-investigation headlines, which keep downside and headline-risk elevated.", "Technicals show a weak/fragile setup (price below key pivot ~41.53, momentum not improving decisively), so you\u2019re not getting a clear \u201cbuy-the-dip\u201d confirmation.", "The bull case (ROSELLA survival data + July 11, 2026 ovarian cancer action date) exists, but the stock is currently trading more like an event-risk name than a clean trend-following opportunity."]
["Trend/levels: Price (40.16) is below the pivot (41.53) \u2192 near-term bias leans bearish/neutral. Nearest support S1 ~36.92 (then S2 ~34.07). Overhead resistance R1 ~46.13 (then R2 ~48.98).", "Momentum: MACD histogram is positive (1.702) but contracting \u2192 prior upside momentum is fading rather than accelerating.", "RSI(6) ~41.9: neutral-to-weak; not oversold enough to signal a high-conviction bounce.", "Moving averages: converging MAs suggest consolidation after the big drawdown, not a confirmed uptrend restart.", "Intellectia Proprietary Trading Signals\n- AI Stock Picker: no signal on given stock today.\n- SwingMax: No signal on given stock recently."]
["Clinical catalyst: Positive Phase 3 ROSELLA overall survival data (platinum-resistant ovarian cancer) has improved the ovarian-cancer thesis in some analyst models.", "Regulatory calendar: FDA action date cited by analysts for ovarian cancer relacorilant is July 11, 2026 (potential major upside catalyst if favorable).", "Core business: Korlym franchise still viewed as \u201cstrong\u201d by some bulls; revenue in the latest reported quarter still grew double-digits YoY.", "Upcoming event: Q4/Dec-2025 earnings on 2026-02-19 (after hours) could reset near-term narrative if guidance/updates surprise positively."]
["Regulatory overhang: FDA Complete Response Letter / NDA rejection narrative has materially damaged confidence and implies added trials and delays (multi-year in some models).", "Headline/legal pressure: Multiple law firms investigating potential securities issues adds persistent negative newsflow.", "Sentiment damage: Recent reports highlight major market-cap loss and shaken investor confidence after the FDA warning/CRL-related headlines.", "Technical risk: If 36.9 support fails, next support zone is ~34, leaving room for further drawdown before stabilization."]
["Latest quarter: 2025/Q3.", "Growth: Revenue 207.64M, +13.75% YoY (top-line trend still positive).", "Profitability: Net income 19.67M, -58.34% YoY; EPS 0.16, -61.90% YoY \u2192 earnings power weakened meaningfully despite revenue growth.", "Margins: Gross margin 97.79% (down slightly YoY), still extremely high, but operating/other costs are pressuring bottom line."]
["Trend summary: After the 2025-12-31 FDA CRL shock, several firms cut price targets sharply (e.g., Canaccord 140\u219299; H.C. Wainwright 145\u219290; Truist 135\u219250) and Wolfe downgraded to Underperform with a $30 target.", "Recent shift: Following January ROSELLA OS data, bullish analysts raised targets again (H.C. Wainwright to $105; Canaccord to $100) while keeping Buy ratings.", "Wall Street pro view (bull case): Korlym durability + ovarian-cancer relacorilant opportunity (potentially large) can justify very large upside targets if regulatory path is favorable.", "Wall Street con view (bear case): Cushing\u2019s/HTN relacorilant path may require another lengthy trial with uncertain payoff; some models remove that opportunity entirely, arguing current value should be materially lower."]
